剂量递增IL-2治疗成人及儿童难治性慢性移植物抗宿主病
该1期试验纳入10例成人和11例儿童激素难治性cGVHD患者,每日给予低剂量IL-2并在第2、4周递增剂量。儿童中9/11例(82%)达部分缓解且皮肤和肺患者报告结局显著改善;成人中5/10例需减量,仅2/7例(29%)达部分缓解。
要点
- 儿童难治性cGVHD接受低剂量IL-2剂量递增安全,部分缓解率达82%。
- 成人超过既往最大耐受剂量递增未改善CD4Treg扩增或临床缓解。
核心结论
- 低剂量IL-2在儿童晚期cGVHD中安全有效,首次证实。
- 成人中超过既往定义的最大耐受剂量递增未改善CD4Treg扩增或临床应答。
研究设计与样本
- 1期试验纳入10例成人和11例儿童激素难治性cGVHD患者(NCT02318082)。
- 儿童起始剂量0.33×10^6 IU/m²/日,成人0.67×10^6 IU/m²/日。
- 第2周和第4周递增剂量,儿童最大1×10^6 IU/m²/日,成人最大2×10^6 IU/m²/日。
- 患者以最大耐受剂量治疗至第8周。
主要发现
- 儿童9/11例(82%)在多个cGVHD部位达部分缓解,包括肺部。
- 儿童皮肤和肺患者报告结局评分显著改善。
- 成人5/10例需减量,仅2/7例可评估患者(29%)第8周达部分缓解。
- 两队列CD4Treg和自然杀伤细胞扩增,常规CD4+ T细胞和CD8+ T细胞无显著变化。
关键数值与推荐
- 儿童部分缓解率82%(9/11),成人部分缓解率29%(2/7)。
临床怎么用
- 儿童难治性cGVHD可考虑低剂量IL-2剂量递增方案。
- 成人不宜超过既往最大耐受剂量递增IL-2,因未改善CD4Treg扩增或临床应答。
局限性
- 1期试验样本量小(成人10例,儿童11例)。
- 成人仅7例可评估部分缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-dose interleukin-2 (IL-2) therapy for chronic graft-versus-host disease (cGVHD) generates a rapid rise in plasma IL-2 levels and CD4+CD25+CD127-Foxp3+ regulatory T-cell (CD4Treg) proliferation, but both decrease over time despite continued daily administration. To test whether IL-2 dose escalation at the time of anticipated falls in plasma levels could circumvent tachyphylaxis and enhance CD4Treg expansion, we conducted a phase 1 trial in 10 adult and 11 pediatric patients with steroid-refractory cGVHD (www.clinicaltrials.gov: NCT02318082). Daily IL-2 was initiated in children and adults (0.33 × 106 and 0.67 × 106 IU/m2 per day, respectively). Dose escalations were scheduled at weeks 2 and 4 to a maximum dose of 1 × 106 IU/m2 per day in children and 2 × 106 IU/m2 per day in adults. Patients continued at their maximum tolerated dose (MTD) until week 8. Children tolerated IL-2 dose escalation with partial responses (PRs) in 9 of 11 patients (82%) at multiple cGVHD sites, including lung. Patient-reported outcome scores for skin and lung improved significantly in pediatric patients. In contrast, 5 of 10 adults required dose reduction, and only 2 of 7 evaluable patients (29%) had PRs at week 8. CD4Tregs and natural killer cells expanded in both cohorts without significant changes in conventional CD4+ T cells (Tcons) or CD8+ T cells. Children achieved a higher median CD4Treg/Tcon ratio at week 8 (0.4 vs 0.18, P = .02) despite lower IL-2 doses. We show for the first time that low-dose IL-2 is safe and effective in children with advanced cGVHD. In adults, escalation above the previously defined MTD did not improve CD4Treg expansion or clinical response.
引用
- Whangbo JS, Kim HT, Mirkovic N, et al. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019. PMID: 31471324. doi:10.1182/bloodadvances.2019000631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。